Checkpoint inhibitor plus rituximab is active in non-Hodgkin lymphomaOctober 31, 2018Aggressive Lymphomas
Line complications plague dose-adjusted EPOCH-R in non-Hodgkin lymphomaOctober 25, 2018Aggressive Lymphomas
Older age predicts mortality after alloHCT in NHL, but not relapseOctober 24, 2018Aggressive Lymphomas
Updated ThroLy system predicts need for thromboprophylaxisOctober 11, 2018Aggressive LymphomasIndolent Lymphoma
